EDITORIALS

The National Cancer Institute and Its Director: Worthy of Our Full Support

Bruce A. Chabner
The Oncologist 2009; 14: 108-109; doi:10.1634/theoncologist.2009-0001
[Full Text] [PDF]  

SUMMARY: Editor-in-Chief of The Oncologist, Bruce A. Chabner, M.D., calls for full support of the National Cancer Institute and its Director, John E. Niederhuber, in the institute's five priorities outlined in the article in this issue by Dr. Niederhuber and colleagues.

Five Strategies for Accelerating the War on Cancer in an Era of Budget Deficits

James H. Doroshow, Robert T. Croyle, John E. Niederhuber
The Oncologist 2009; 14: 110-116; doi:10.1634/theoncologist.2008-0270
[Abstract] [Full Text] [PDF]  

SUMMARY: This article discusses five national-level actions recommended by the National Cancer Institute to continue the advancement of scientific progress on the public health and realize the opportunity of significant, population-level changes in cancer mortality.

Stone Soup: Commentary on "Five Strategies for Accelerating the War on Cancer in an Era of Budget Deficits"

Robert C. Young
The Oncologist 2009; 14: 117-118; doi:10.1634/theoncologist.2009-0008
[Full Text] [PDF]  

SUMMARY: This commentary critically examines the five strategies proposed by the NCI to accelerate the war on cancer in this era of budget deficits.

Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies

Michael J. Guarino, Charles J. Schneider, Martha A. Hosford, Julie R. Brahmer, Charles M. Rudin, Friedrich Graf Finckenstein, Robyn E. Philip-Norton, Haolan Lu, Martin R. Weber, David S. Ettinger
The Oncologist 2009; 14: 119-124; doi:10.1634/theoncologist.2008-0124
[Abstract] [Full Text] [PDF] [Supplemental Data]  

SUMMARY: This study investigates the optimal dose of the antiepidermal growth factor receptor monoclonal antibody cetuximab that can be safely administered in combination with a standard daily dose of erlotinib in patients with advanced solid malignancies.

Management of Mucin-Producing Cystic Neoplasms of the Pancreas

Stefan Fritz, Andrew L. Warshaw, Sarah P. Thayer
The Oncologist 2009; 14: 125-136; doi:10.1634/theoncologist.2008-0200
[Abstract] [Full Text] [PDF]  

SUMMARY: This review describes the clinical presentation, diagnosis, and treatment of mucinous cystic neoplasms of the pancreas. Suggested guidelines derived from what is currently known are provided.

Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?

Cesare Gridelli, Paolo Maione, Antonio Rossi, Marianna Luciana Ferrara, Maria Anna Bareschino, Clorinda Schettino, Paola Claudia Sacco, Fortunato Ciardiello
The Oncologist 2009; 14: 137-147; doi:10.1634/theoncologist.2008-0152
[Abstract] [Full Text] [PDF]  

SUMMARY: This study examines the role of maintenance therapy, or early second-line treatment, with chemotherapy or molecularly targeted agents in prolonging survival times in non-small cell lung cancer patients.

Early-Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?

Marina P. Siakantaris, Gerassimos A. Pangalis, Evangelia Dimitriadou, Flora N. Kontopidou, Theodoros P. Vassilakopoulos, Christina Kalpadakis, Sotirios Sachanas, Xanthi Yiakoumis, Penelope Korkolopoulou, Marie-Christine Kyrtsonis, Panayia Bobotsis, Athina Androulaki, Eustratios Patsouris, Panayiotis Panayiotidis, Maria K. Angelopoulou
The Oncologist 2009; 14: 148-154; doi:10.1634/theoncologist.2008-0178
[Abstract] [Full Text] [PDF]  

SUMMARY: This study investigates the incidence of occult blood disease in early-stage gastric mucosa-associated lymphoid tissue lymphoma patients, its impact on clinical outcome, and the similarity between blood and gastric lymphocytic clones.

Oligodendrogliomas: Molecular Biology and Treatment

Jacolien E. C. Bromberg, Martin J. van den Bent
The Oncologist 2009; 14: 155-163; doi:10.1634/theoncologist.2008-0248
[Abstract] [Full Text] [PDF]  

SUMMARY: This manuscript reviews recent developments in the research and treatment of oligodendroglial tumors.

Malignancy in Children with Trisomy 21

Karen R. Rabin, James A. Whitlock
The Oncologist 2009; 14: 164-173; doi:10.1634/theoncologist.2008-0217
[Abstract] [Full Text] [PDF]  

SUMMARY: This review highlights the epidemiology of cancer in Down syndrome, the clinical features and biology of the leukemias that are most common in Down syndrome, and the pharmacogenetic considerations specific to this population.

Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors

Martin H. Cohen, Ann Farrell, Robert Justice, Richard Pazdur
The Oncologist 2009; 14: 174-180; doi:10.1634/theoncologist.2008-0255
[Abstract] [Full Text] [PDF]  

SUMMARY: The manuscript reviews the results of two open-label, controlled, multicenter, intergroup, international, randomized phase III studies of imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors, which constituted the postmarketing commitment of the manufacturer to provide long-term efficacy and safety data.

Bisphosphonates in Oncology: Rising Stars or Fallen Heroes

Tim Van den Wyngaert, Manon T. Huizing, Eric Fossion, Jan B. Vermorken
The Oncologist 2009; 14: 181-191; doi:10.1634/theoncologist.2008-0209
[Abstract] [Full Text] [PDF]  

SUMMARY: This manuscript reviews the available body of clinical trials supporting the use of bisphosphonates in oncology, showing the benefits of bisphosphonate use in metastatic disease, the prevention of treatment-induced bone loss and emerging evidence on the antitumor potential of some of these agents when used in the adjuvant setting. The risk for osteonecrosis of the jaw is also discussed.

The CAIRO and FOCUS Studies: Which Lesson Is to Be Learned?

Miriam Koopman, Matthew T. Seymour, Cornelis J. A. Punt
The Oncologist 2009; 14: 192-193; doi:10.1634/theoncologist.2008-0247
[Full Text] [PDF]  

SUMMARY: This letter assesses results presented by Drs. O'Neil and Goldberg in a recent update of clinical trials in metastatic colorectal cancer published in The Oncologist.

In Reply

Bert H. O'Neil, Richard M. Goldberg
The Oncologist 2009; 14: 194-196; doi:10.1634/theoncologist.2008-0291
[Full Text] [PDF]  

SUMMARY: Drs. O'Neil and Goldberg respond to the Koopman et al. letter.

Anti-Inflammatory Cream Reduces Skin Damage Induced by Ionizing Radiation

Philippe F. Simard, Rachel M. Bolton, Nancy J. Tarbell
The Oncologist 2009; 14: 197-198; doi:10.1634/theoncologist.2008-0256
[Full Text] [PDF]  

SUMMARY: The authors assessed whether the use of a topical anti-inflammatory agent at the radiation entry site would prevent radiation-induced skin damage and found that the use of a topical anti-inflammatory agent, such as one containing 10% trolamine salicylate, may reduce skin damage at the radiation entry site if used prophylactically.

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.